Can any of the company-specific risk be diversified away by investing in both Avadel Pharmaceuticals and Intracellular at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Avadel Pharmaceuticals and Intracellular into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Avadel Pharmaceuticals PLC and Intracellular Th, you can compare the effects of market volatilities on Avadel Pharmaceuticals and Intracellular and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Avadel Pharmaceuticals with a short position of Intracellular. Check out your portfolio center. Please also check ongoing floating volatility patterns of Avadel Pharmaceuticals and Intracellular.
Diversification Opportunities for Avadel Pharmaceuticals and Intracellular
The 3 months correlation between Avadel and Intracellular is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Avadel Pharmaceuticals PLC and Intracellular Th in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Intracellular Th and Avadel Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Avadel Pharmaceuticals PLC are associated (or correlated) with Intracellular. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Intracellular Th has no effect on the direction of Avadel Pharmaceuticals i.e., Avadel Pharmaceuticals and Intracellular go up and down completely randomly.
Pair Corralation between Avadel Pharmaceuticals and Intracellular
Given the investment horizon of 90 days Avadel Pharmaceuticals PLC is expected to under-perform the Intracellular. But the stock apears to be less risky and, when comparing its historical volatility, Avadel Pharmaceuticals PLC is 1.35 times less risky than Intracellular. The stock trades about -0.01 of its potential returns per unit of risk. The Intracellular Th is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest 6,603 in Intracellular Th on March 6, 2024 and sell it today you would earn a total of 238.00 from holding Intracellular Th or generate 3.6% return on investment over 90 days.
Over the last 90 days Avadel Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Avadel Pharmaceuticals is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.
Compared to the overall equity markets, risk-adjusted returns on investments in Intracellular Th are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental indicators, Intracellular may actually be approaching a critical reversion point that can send shares even higher in July 2024.